Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called TAK-341 or…
Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) $10.2 billion in milestones, puts the biologics at the center of…
After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its remaining strategic commitment by reupping a pact with AI drug…